Investors / Kerna Ventures
Kerna Ventures
Venture capital
Kerna Ventures is an investment firm with a portfolio of 17 companies. It invests at the seed to Series B stage in biotechnology companies.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsgene editinggene therapyrna therapeuticsdrug delivery
Your fit with Kerna Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsKerna Ventures lists 13 checked portfolio companies on its own site and is named in 4 funding rounds. Its most frequent entry is Seed, 75% of the companies with a known first round. Its largest themes are Healthcare & Biotech (92%) and Real Estate & Construction (8%). 50% of its companies are based in United States. It invests most often alongside Angelini Ventures, 4BIO Capital and Berkeley Frontier Fund.
Counts come from funding rounds that name Kerna Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Kerna Ventures' whole history. Rounds on record name 4 companies; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 75% |
| Series A | 25% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 3 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 82th | 75% of entries at pre-seed or seed |
| Evidence | 87th | 15% of companies confirmed by a round |
| Sector focus | 96th | 92% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Angelini Ventures | 3 |
| 4BIO Capital | 2 |
| Berkeley Frontier Fund | 2 |
| ACVC Partners | 1 |
| ARCH Venture Partners | 1 |
| Ada Ventures | 1 |
| AlbionVC | 1 |
| Backed | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 92% | 15% |
| Real Estate & Construction | 8% | 3% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Angelini Ventures
Compare Kerna Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Kerna Ventures| Date | Company | Stage |
|---|---|---|
| 13 Oct 2026 | Seed | |
| 6 Oct 2026 | Series A | |
| 29 Sept 2026 | Seed | |
| 1 Oct 2025 | Seed |
Round details for Kerna Ventures
Amounts, full round histories and every co-investor in Kerna Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aerska develops RNA medicines to treat diseases of the brain | Healthcare & Biotech | Oct 2025Seed | Page + round | |
| AptaDir develops RNA-based therapeutics to reprogram DNA methylation in disease conditions | Healthcare & Biotech | Sept 2026Seed | Funding round | |
| Arbor Biotechnologies develops novel gene editing treatments for people living with genetic disease | Healthcare & Biotech | Portfolio page | ||
| Axent Biosciences is a biotechnology therapeutics company developing next-generation cell therapies using engineered biomaterials. | Healthcare & Biotech | Portfolio page | ||
| BreezeBio is solving the problem of targeted delivery of genetic medicines with a fresh approach. | Healthcare & Biotech | Portfolio page | ||
| Cavalry Biosciences develops precision medicines based on IGF-1, a growth factor, to treat various diseases | Healthcare & Biotech | Portfolio page | ||
| Epicrispr Biotechnologies develops therapies to dynamically control gene expression and treat complex disease | Healthcare & Biotech | Portfolio page | ||
| Focalis Bio is a biotech company developing cutting-edge gene therapies targeting focal refractory epilepsy (FRE) | Healthcare & Biotech | Portfolio page | ||
| Kamal Therapeutics develops intravenous recombinant human decorin to treat dystrophic epidermis bullosa. | Healthcare & Biotech | Portfolio page | ||
| LandTech connects every dataset needed to make confident, evidence-based decisions for land development in one place | Real Estate & Construction | Portfolio page | ||
| RougeTx is developing small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction | Healthcare & Biotech | Oct 2026Series A | Page + round | |
| UndecimalBio pairs massive scale combinatorial chemistry with transformer-based AI to guide siRNA therapeutics into the tissues that need them. | Healthcare & Biotech | Oct 2026Seed | Funding round | |
| Vivere Oncotherapies develops next-generation cancer therapies that activate the immune system to detect and destroy cancer cells | Healthcare & Biotech | Portfolio page |
About this data
site last read 7 Nov 2026- Site
- kerna.vc
- Last read
- 7 Nov 2026
- Watching since
- 7 Nov 2026
- Rounds since
- 1 Oct 2025
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Kerna Ventures' profile as data
Pull Kerna Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/kerna.vc
# also
GET /v1/firms/kerna.vc/portfolio
GET /v1/firms/kerna.vc/coinvestors
GET /v1/firms/kerna.vc/news